|2012 Focused Update Recommendations||2012 Comments|
|1. Creatinine clearance should be estimated in UA/NSTEMI patients and the doses of renally cleared medications should be adjusted according to the pharmacokinetic data for specific medications (162,163). (Level of Evidence: B)||2011 recommendation remains current.|
|2. Patients undergoing cardiac catheterization with receipt of contrast media should receive adequate preparatory hydration (164,165). (Level of Evidence: B)||2011 recommendation remains current.|
|3. Calculation of the contrast volume to creatinine clearance ratio is useful to predict the maximum volume of contrast media that can be given without significantly increasing the risk of contrast-associated nephropathy (166,167). (Level of Evidence: B)||2011 recommendation remains current.|
|1. An invasive strategy is reasonable in patients with mild (stage 2) and moderate (stage 3) CKD (162,163,168,169). (Level of Evidence: B) (There are insufficient data on benefit/risk of invasive strategy in UA/NSTEMI patients with advanced CKD [stages 4, 5].)||2011 recommendation remains current.|
CKD indicates chronic kidney disease; and UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction.